Christian Schnell

TL;DR: The preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties, and the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.

TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.

TL;DR: A novel compound with therapeutic potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role, PTK787/ZK 222584 is very well tolerated and does not impair wound healing.

TL;DR: Aliskiren is the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases and employs a combination of molecular modelling and crystallographic structure analysis to design renin inhibitor lacking the extended peptide-like backbone of earlier inhibitors.

TL;DR: The biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models and behaves synergistically when combined with either targeted agentssuch as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.